This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AB-25E9

Alethia BioTherapeutics Inc.

Drug Names(s): AB-25E9

Description: AB-25E9 is a monoclonal antibody that inhibits osteoclast differentiation and bone resorption. It targets Siglec-15, a cell-surface protein specifically expressed on osteoclasts.


AB-25E9 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug